RxDoctor Payments Data

Anne Lake, APRN

Family · Archdale, NCNPI 1053391409

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $206,894 of the $306,449 with a category attached, or 67.5%. Amgen accounts for 92.4% of it on its own, with 4 other manufacturers making up the rest. Among family clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$306,449in general payments, 2019–2025

Across 369 payments — averaging $830.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$283K
  • Radius Health, Inc.$21K
  • Lilly USA, LLC$1K
  • AstraZeneca$525
  • UCB, Inc.$30

What the payments were for

  • Consulting fees$4,7002%
  • Speaking & faculty fees$206,89468%
  • Travel & lodging$87,94429%
  • Food & beverage$6,9122%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen335$283,304
Radius Health, Inc.30$21,390
Lilly USA, LLC1$1,200
AstraZeneca2$525
UCB, Inc.1$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$306,449 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$31,024
Medicare patients
443
Services billed
604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ForteoTeriparatide83$342,967
ProliaDenosumab63$107,941
TymlosAbaloparatide33$102,830
Teriparatide18$69,272
Evenity (2 Syringes)Romosozumab-Aqqg21$50,868
MyrbetriqMirabegron18$3,878
Alendronate Sodium244$1,749
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic14$784
Memantine Hcl11$120
Duloxetine Hcl12$108
Rosuvastatin Calcium11$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCForteo$1,200$342,96783 claims
AmgenProlia, Evenity (2 Syringes)$283,304$158,80984 claims
Radius Health, Inc.Tymlos$21,390$102,83033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Archdale

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →